Cargando…
Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
There has been a dearth of new drugs approved for cardiovascular disorders. The cost is prohibitive, averaging to $2.5 billion, and requiring 12.5 years. This is in large part due to the high failure rate, with only 5% approval by the Food and Drug Administration. Despite preclinical studies showing...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234613/ https://www.ncbi.nlm.nih.gov/pubmed/30456340 http://dx.doi.org/10.1016/j.jacbts.2018.08.001 |